poolbegpharma.comCrawled Nov 8, 2026
Using artificial intelligence to analyse unique human challenge trial data, Poolbeg Pharma has identified novel drug targets and treatments for RSV and influenza
Delivering immune stimulating antigens to specific areas of the gut, using proprietary encapsulation technologies, with the objective of activating protective mucosal immunity
Clinical programmes targetting diseases with high unmet need including cancer immunotherapy-induced CRS, infectious disease and oral GLP-1R agonist for obesity
Biopharma companies and nonprofits focus deal activity on infectious diseases beyond COVID-19, including smallpox and influenza.
Poolbeg Pharma’s media section includes corporate videos, interviews, and presentations.
Poolbeg Pharma provides downloadable images, company descriptions, and logos for editorial use.
Stay up to date with Poolbeg's latest news, interviews, and events.
Poolbeg Pharma appears in news and media as a biopharmaceutical company targeting diseases with high unmet medical needs.
Poolbeg Pharma recruits for its team, which develops programs addressing critical unmet medical needs.
Contact details for Poolbeg Pharma’s advisers—including Financial PR, Nominated Adviser, Broker, Solicitors, Auditor, and Registrar—are available.
Poolbeg Pharma highlights its leadership team, board of directors, and scientific advisory board.
Poolbeg Pharma is a biopharmaceutical company addressing diseases with high unmet medical needs.
Poolbeg Pharma is a publicly listed biopharmaceutical company targeting diseases with high unmet medical needs.
Poolbeg Pharma is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field.
Poolbeg Pharma’s privacy statement explains how it collects, uses, and shares personal data.
